Aurinia Pharmaceuticals reports Q4 EPS (18c), consensus (27c)

Reports Q4 revenue $28.4M, consensus $27.78M. As of December 31, 2022, Aurinia had cash, cash equivalents and restricted cash and investments of $389.4M, compared to $466.1M at December 31, 2021. Aurinia believes that it has sufficient financial resources to fund its operations for at least the next few years. "2022 was a year of significant growth generating $134.0 million in total net revenue representing a 194% increase over the previous year. As an organization, we continue to advocate for improved screening, diagnosis and the treatment of lupus nephritis with healthcare providers while reinforcing the clinical benefits of LUPKYNIS over the historic standard of care," said CEO Peter Greenleaf. "We are focused on operational and commercial execution and are poised for continued growth in and outside the U.S., as we work to change the course of lupus nephritis and other autoimmune diseases."